BiotechTube
Bio4t2

Bio4t2

Cambridge, United States· Est.
bio4t2.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.3M

Overview

Bio4t2 is pioneering a multi-technology platform approach to overcome the historic challenges of applying CAR-T therapy to solid tumors. Its core PrismCore platform generates CARs with antigen-density-dependent activation, aiming to selectively target tumors while sparing healthy tissue. The company's lead asset, B4t2-001, is in clinical testing, and its pipeline includes a next-generation bispecific Bi-CAR-T product. Bio4t2's innovations in engraftment without preconditioning chemotherapy and integrated safety controls position it as a potential disruptor in the solid tumor cell therapy space.

Oncology

Technology Platform

PrismCore™ (antigen-density calibrated CAR design), Bio-Engine™ (chemotherapy-free persistence/engraftment), Bio-Strike™ (safety switch). Integrated platform for developing CAR-T for solid tumors.

Funding History

2
Total raised:$4.3M
Grant$1.8M
Seed$2.5M

Opportunities

The solid tumor CAR-T market represents a massive, largely untapped opportunity far exceeding the current blood cancer CAR-T market.
Bio4t2's technology addresses key limitations (safety, persistence, antigen escape) that have held the field back.
Eliminating preconditioning chemotherapy could reduce treatment complexity, cost, and toxicity, improving patient access and commercial appeal.

Risk Factors

High clinical risk that its lead asset fails to show sufficient safety/efficacy in humans against the complex biology of solid tumors.
Intense competition from numerous other biotechs and pharma companies pursuing similar goals.
Financial dependency on external capital as a pre-revenue company.

Competitive Landscape

Bio4t2 competes in the crowded and rapidly evolving field of solid tumor cell therapy. Competitors range from large pharma (e.g., Novartis, Gilead, BMS) to many biotechs exploring strategies like TCRs, TILs, and other next-gen CAR-Ts with armorings or logic-gated designs. Differentiation hinges on demonstrating superior safety/efficacy from its integrated platform in clinical trials.

More companies in Cell & Gene Therapy →More companies in United States →